Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders' Equity

v3.21.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Underwritten Public Offering
Warrant Redemption
Roivant Sciences Ltd. (RSL)
Series A  preferred stock
Common stock
Common stock
Underwritten Public Offering
Common stock
Upon Achievement of Earnout Shares Milestone
Common stock
Warrant Redemption
Additional paid-in capital
Additional paid-in capital
Underwritten Public Offering
Additional paid-in capital
Upon Achievement of Earnout Shares Milestone
Additional paid-in capital
Warrant Redemption
Additional paid-in capital
Roivant Sciences Ltd. (RSL)
Accumulated other comprehensive income (loss)
Accumulated deficit
Beginning balance (in shares) at Mar. 31, 2020         10,000 54,655,376                    
Beginning balance at Mar. 31, 2020 $ 94,069         $ 5       $ 185,306         $ (16) $ (91,226)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Issuance of common stock (in shares)             9,613,365 10,000,000 5,719,145              
Issuance of common stock   $ 130,428 $ 65,752       $ 1 $ 1 $ 1   $ 130,427 $ (1) $ 65,751      
Vesting of sponsor restricted shares (in shares)           900,000                    
Stock options exercised (in shares)           23,841                    
Stock options exercised 63                 63            
Capital contribution – stock-based compensation 63                 63            
Capital contribution – expenses allocated from Roivant Sciences Ltd.       $ 164                   $ 164    
Stock-based compensation 3,918                 3,918            
Foreign currency translation adjustments 26                           26  
Net loss (26,708)                             (26,708)
Ending balance (in shares) at Jun. 30, 2020         10,000 80,911,727                    
Ending balance at Jun. 30, 2020 267,775         $ 8       385,691         10 (117,934)
Beginning balance (in shares) at Mar. 31, 2021         10,000 97,971,243                    
Beginning balance at Mar. 31, 2021 391,480         $ 10       590,425         (298) (198,657)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Restricted stock units vested and settled (in shares)           6,352                    
Capital contribution – stock-based compensation 41                 41            
Capital contribution – expenses allocated from Roivant Sciences Ltd.       $ 91                   $ 91    
Stock-based compensation 3,820                 3,820            
Foreign currency translation adjustments 571                           571  
Net loss (30,471)                             (30,471)
Ending balance (in shares) at Jun. 30, 2021         10,000 97,977,595                    
Ending balance at Jun. 30, 2021 $ 365,532         $ 10       $ 594,377         $ 273 $ (229,128)